# The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

> **NCT02409290** · PHASE3 · COMPLETED · sponsor: **IUATLD, Inc** · enrollment: 588 (actual)

## Conditions studied

- MDR-TB

## Interventions

- **DRUG:** Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
- **DRUG:** Moxifloxacin
- **DRUG:** Clofazimine
- **DRUG:** Ethambutol
- **DRUG:** Pyrazinamide
- **DRUG:** Isoniazid
- **DRUG:** Prothionamide
- **DRUG:** Kanamycin
- **DRUG:** Levofloxacin
- **DRUG:** Bedaquiline

## Key facts

- **NCT ID:** NCT02409290
- **Lead sponsor:** IUATLD, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2022-05-13
- **Final completion:** 2023-05-02
- **Target enrollment:** 588 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02409290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02409290, "The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02409290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*